Clinical trials: Controlled Diabetes
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- SURMOUNT-2 (NCT04657003)
- Testing
- Tirzepatide
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 938 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
- Trial name
- NCT00722371
- Testing
- Sitagliptin phosphate, Pioglitazone hydrochloride, Metformin
- Volunteers
- 1,615 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
- Trial name
- NCT00660907
- Testing
- dapagliflozin, glipizide, metformin hydrochloride
- Where
- 76 sites in Argentina, France and 8 more
- Volunteers
- 1,217 people
- Sponsor
- AstraZeneca
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic peripheral neuropathy.
- Trial name
- NCT02427464
- Testing
- Engensis (VM202)
- Where
- 25 sites in United States
- Volunteers
- 507 people
- Sponsor
- Helixmith Co., Ltd.
Diabetes Mellitus
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or…
- Trial name
- NCT02182895
- Testing
- Saxagliptin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from…
- Trial name
- NCT00734474
- Testing
- LY2189265, Sitagliptin, Metformin
- Where
- 99 sites in United States, Canada and 11 more
- Volunteers
- 1,202 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-South (NCT01217463)
- Testing
- Trafermin 0.01% spray
- Where
- 24 sites in Czechia, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Olympus Biotech Corporation
Type 2 Diabetes Mellitus
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
This study will examine the safety and efficacy of the addition of omarigliptin in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin and glimepiride.
- Trial name
- NCT01704261
- Testing
- Omarigliptin, Glimepiride, Metformin
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
The purpose of this study is to determine whether ceasing sitagliptin and switching to exenatide and metformin is non-inferior to adding exenatide to sitagliptin and metformin, in those patients with type 2 diabetes who are…
- Trial name
- NCT00870194
- Testing
- exenatide and sitagliptin
- Where
- 36 sites in Argentina, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
- Trial name
- NCT00849056
- Testing
- albiglutide
- Where
- 331 sites in United States, India and 4 more
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcer, Diabetes Mellitus
CSTC1 for Diabetic Foot Ulcers Phase II Study
The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Diabetes Mellitus, Wounds
- Trial name
- NCT01813305
- Testing
- CSTC1, CSTC1 Matched vehicle
- Where
- Taiwan
- Volunteers
- 124 people
- Sponsor
- Charsire Biotechnology Corp.
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment, and to assess the overall safety and tolerability of canagliflozin.
- Trial name
- NCT03170518
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 106 sites in United States, Brazil and 8 more
- Volunteers
- 171 people
- Sponsor
- Janssen Research & Development, LLC
Heart Failure, Diabetes
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D)…
- Trial name
- NCT04249778
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Emory University
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.